Evidence‐based recommendations for the use of WBC‐reduced cellular blood components

Ratko, Thomas A; Cummings, Joseph; Oberman, Harold A.; Crookston, Kendall P.; DeChristopher, Phillip J.; Eastlund, D. Ted; Godwin, John; Sacher, Ronald A.; Yawn, David H.; Matuszewski, Karl A.

doi:10.1046/j.1537-2995.2001.41101310.x

Cited by 60 publications

(33 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[36][37][38][39][40] Similarly, the other predicted advantages of prestorage leukoreduction, such as a reduction in transfusion-associated infections and posttransfusion immune suppression, require further study. [41][42][43][44] If these benefits are confirmed they will add support to the results of this study and the growing body of literature in favor of prestorage leukoreduction.…”

Section: Discussionsupporting

confidence: 68%

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

Seftel

Growe

Petraszko

et al. 2004

Blood

126

View full text Add to dashboard Cite

Randomized controlled trials have shown a reduction in platelet alloimmunization and refractoriness in patients with acute leukemia (AL) with the use of poststorage leukoreduction of blood products. Universal prestorage leukoreduction (ULR) of red cell and platelet products has been performed in Canada since August 1999. We conducted a retrospective analysis of 13 902 platelet transfusions in 617 patients undergoing chemotherapy (CT) for AL or stem cell transplantation (SCT) before (n ‫؍‬ 315) and after (n ‫؍‬ 302) the introduction of ULR. Alloimmunization was significantly reduced (19% to 7%, P < .001) in the post-ULR group. Alloimmune platelet refractoriness was similarly reduced (14% to 4%, P < .001). Fewer patients in the post-ULR group received HLA-matched platelets (14% vs 5%, P < .001). Alloimmunization and alloimmune refractoriness in the 318 patients who were previously pregnant and/or transfused were also reduced after ULR (P ‫؍‬ .023 and P ‫؍‬ .005, respectively). In a Cox regression model, the 3 independent factors that predicted for alloimmune refractoriness were nonleukoreduced blood

show abstract

Section: Discussionsupporting

confidence: 68%

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

Seftel

Growe

Petraszko

et al. 2004

Blood

126

View full text Add to dashboard Cite

show abstract

“…The latter may result in red blood cell alloimmunization, transplant rejection, febrile reactions, and refractoriness to platelet transfusions (39). Despite mounting evidence regarding the adverse consequences of leukocyte contamination of blood products, it continues to be a matter of debate whether the evidence is compelling enough to justify the cost of universal prestorage leukoreduction of blood products (40)(41)(42)(43)(44)(45)(46)(47). Despite the debate, many European countries have already adopted universal leukoreduction of blood products.…”

Section: Effect Of Leukocyte Depletion On Risk Of Hla Sensitization Amentioning

confidence: 99%

Effect of Red Cell Transfusions on Future Kidney Transplantation

Obrador

Macdougall

2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryRed cell transfusions, erythropoiesis-stimulating agents (ESAs), and intravenous iron therapy all have a place in the treatment of anemia associated with CKD. Their relative merits and uses are subject to many clinical and nonclinical factors. New concerns associated with the use of ESA therapy make it likely that the use of blood transfusions will increase, refueling previous debates about their associated risks. Data on whether red cell transfusions increase sensitization to HLA antigens, rendering subsequent transplantation more problematic, are mainly derived from older literature. Older data suggested that women were more at risk of HLA sensitization than men, particularly those with previous multiple pregnancies, although recent U.S. Renal Data System data have challenged this. HLA sensitization prolongs the waiting time for transplantation and reduces graft survival. Leukocyte depletion of red cells does not appear to reduce the risk of HLA sensitization. This review summarizes much of the data on these issues, as well as highlighting the need for further research on the potential risks for blood transfusion in patients with CKD.

show abstract

“…Nearly 14 million units of blood are donated annually in the USA, and about 4 million people receive BT every year [1,2]. Blood transfusion administration in surgical and critical care settings varies between 30-100% of patients.…”

Section: Editorialmentioning

confidence: 99%

The Negative Influence and Adverse Outcome of Blood Transfusion in Heart Surgery Patients

2016

JCCR

View full text Add to dashboard Cite

Evidence‐based recommendations for the use of WBC‐reduced cellular blood components

Cited by 60 publications

References 61 publications

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

Effect of Red Cell Transfusions on Future Kidney Transplantation

The Negative Influence and Adverse Outcome of Blood Transfusion in Heart Surgery Patients

Contact Info

Product

Resources

About